Chemokine polymorphisms and lymphoma: A pooled analysis

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 497-506

  Bracci, Paige M ^a   Skibola, Christine F ^b   Conde, Lucia ^b   Halperin, Eran ^c   Lightfoot, Tracy ^d   Smith, Alex ^d   Paynter, Randi A ^b   Skibola, Danica R ^b   Agana, Luz ^b   Roman, Eve ^d   Kane, Eleanor ^d   Wiencke, John K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INTERNATIONAL COMPUTER SCIENCE INSTITUTE   (United States)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Casecontrol; Chemokines; Genetic; Lymphoma non Hodgkin; Polymorphism

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; RANTES; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; ADOLESCENT; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; GENETICS; HAPLOTYPE; LYMPHOMA; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HAPLOTYPES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS;

EID: 77249167170     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903518337     Document Type: Article

References (51)

1. Hartge P, Wang S, Bracci P, Holly E, Devesa S. Non-Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JJ, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2006.
2. Skibola CF, Bracci PM, Halperin E, et al. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS One 2008;3:e2816.
3. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5- delta32 mutation. Cancer Res 1999;59:3561-3564.
4. Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus- 1-infected individuals. Blood 1999;93:1838-1842.
5. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene ''intercrine'' cytokine family. Annu Rev Immunol 1991;9:617-648.
6. Pease JE, Williams TJ. The attraction of chemokines as a target for specific anti-inflammatory therapy. Br J Pharmacol 2006;147:S212-S221.
7. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
8. Rollins BJ. Chemokines. Blood 1997;90:909-928.
9. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143-154.
10. Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001; 15:752-756.
11. Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clin Proc 2004;79:318-325.
12. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000;96:685-690.
13. Trentin L, Cabrelle A, Facco M, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004;104:502-508.
14. Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma 2004;45: 2491-2496.
15. Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009;47:412-418.
16. Hirata H, Hinoda Y, Kikuno N, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 2007;13:5056-5062.
17. Liou JM, Lin JT, Huang SP, et al. RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol 2008;43:115-123.
18. Soria G, Ben-Baruch A. The CCL5/CCR5 axis in cancer. In: Fulton A, editor. Chemokine receptors in cancer. New York: Humana Press; 2009.
19. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009;25:25.
20. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-4038.
21. Kunkel SL, Godessart N. Chemokines in autoimmunity: from pathology to therapeutics. Autoimmun Rev 2002;1:313-320.
22. Giltay EJ, Fonk JC, Von Blomberg BM, Drexhage HA, Schalkwijk C, Gooren LJ. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab 2000;85:1648-1657.
23. Mo R, Chen J, Grolleau-Julius A, Murphy HS, Richardson BC, Yung RL. Estrogen regulates CCR gene expression and function in T lymphocytes. J Immunol 2005;174:6023-6029.
24. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521-574.
25. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;150:375-389.
26. Willett EV, Smith AG, Dovey GJ, Morgan GJ, Parker J, Roman E. Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma. Cancer Causes Control 2004;15: 771-780.
27. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112-2135.
28. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287:2274-2277.
29. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-965.
30. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
31. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
32. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Ann Rev Immunol 2007;25:787-820.
33. IVan sson EL, Gustavsson IM, Magnusson JJ, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007;121:2451-2457.
34. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:726-731.
35. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 2006;25:357-371.
36. Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006;58:962-974.
37. Chelli M, Alizon M. Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor. J Biol Chem 2001;276:46975-46982.
38. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:405-408. (Pubitemid 46548641)
39. Saenz-Lopez P, Carretero R, Cozar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008;8: 382.
40. Al-Abdulhadi SA, Helms PJ, Main M, Smith O, Christie G. Preferential transmission and association of the -403 G -4 A promoter RANTES polymorphism with atopic asthma. Genes Immun 2005;6:24-30.
41. Nickel RG, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000;164:1612-1616.
42. Tanaka K, Roberts MH, Yamamoto N, Sugiura H, Uehara M, Hopkin JM. Upregulating promoter polymorphisms of RANTES relate to atopic dermatitis. Int J Immunogenet 2006;33:423-428.
43. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002;62:1093-1102.
44. Ek S, Bjorck E, Hogerkorp CM, Nordenskjold M, Porwit- MacDonald A, Borrebaeck CA. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 2006;118:2092-2097.
45. Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197-201.
46. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002;118:915-922.
47. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003;90:187-194.
48. Levy JA. The unexpected pleiotropic activities of RANTES. J Immunol 2009;182:3945-3946.
49. Lucotte G. Frequencies of 32 base pair deletion of the (Delta 32) allele of the CCR5 HIV-1 co-receptor gene in Caucasians: a comparative analysis. Infect Genet Evol 2002;1:201-205.
50. Mlynarski WM, Placha GP, Wolkow PP, Bochenski JP, Warram JH, Krolewski AS. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes 2005;54:3331-3335.
51. Fischer A, Valentonyte R, Nebel A, et al. Female-specific association of C-C chemokine receptor 5 gene polymorphisms with Lofgren's syndrome. J Mol Med 2008;86:553-561.